e-Therapeutics plc Announces Recruitment Resumes Into UK Phase I ETS2101 Cancer Trial
3/26/2014 9:55:55 AM
OXFORD & NEWCASTLE, England--(BUSINESS WIRE)--e-Therapeutics plc (AIM:ETX) announces today that it has received approval from MHRA to recommence recruitment of new patients into its ETS2101 phase Ia solid tumours trial being conducted at three centres in the UK. Recruitment was temporarily paused due to a drug storage issue which has now been resolved to the satisfaction of the UK Regulatory Body, allowing the trial to continue to higher doses in further cohorts of patients. Patients already receiving treatment with ETS2101 at the time of the temporary halt in recruitment continued to be dosed in accordance with trial protocols.
Help employers find you! Check out all the jobs and post your resume.
comments powered by